WO2000004888A3 - Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury - Google Patents

Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury Download PDF

Info

Publication number
WO2000004888A3
WO2000004888A3 PCT/GB1999/002311 GB9902311W WO0004888A3 WO 2000004888 A3 WO2000004888 A3 WO 2000004888A3 GB 9902311 W GB9902311 W GB 9902311W WO 0004888 A3 WO0004888 A3 WO 0004888A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
nervous system
central nervous
cyclodextrins
system injury
Prior art date
Application number
PCT/GB1999/002311
Other languages
French (fr)
Other versions
WO2000004888A2 (en
Inventor
Alan John Nelson
Original Assignee
Cerebrus Pharm Ltd
Alan John Nelson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerebrus Pharm Ltd, Alan John Nelson filed Critical Cerebrus Pharm Ltd
Priority to AU50508/99A priority Critical patent/AU5050899A/en
Publication of WO2000004888A2 publication Critical patent/WO2000004888A2/en
Publication of WO2000004888A3 publication Critical patent/WO2000004888A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The use of a substituted or unsubstituted cyclodextrin as the active agent in the manufacture of a medicament for the treatment of cerebral ischaemia or central nervous system injury.
PCT/GB1999/002311 1998-07-20 1999-07-19 Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury WO2000004888A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50508/99A AU5050899A (en) 1998-07-20 1999-07-19 Chemical compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9815785.2 1998-07-20
GBGB9815785.2A GB9815785D0 (en) 1998-07-20 1998-07-20 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2000004888A2 WO2000004888A2 (en) 2000-02-03
WO2000004888A3 true WO2000004888A3 (en) 2000-04-27

Family

ID=10835840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002311 WO2000004888A2 (en) 1998-07-20 1999-07-19 Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury

Country Status (3)

Country Link
AU (1) AU5050899A (en)
GB (1) GB9815785D0 (en)
WO (1) WO2000004888A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
LU100797B1 (en) * 2018-05-15 2019-11-15 Univ Luxembourg 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition
WO2023123468A1 (en) * 2021-12-31 2023-07-06 杭州奥默医药股份有限公司 Cardiovascular and cerebrovascular drug and use thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0169725A2 (en) * 1984-07-23 1986-01-29 Ono Pharmaceutical Co., Ltd. Prostaglandin analogues for the treatment of brain cells anoxia
WO1992002256A1 (en) * 1990-08-01 1992-02-20 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
EP0501552A1 (en) * 1991-02-25 1992-09-02 Janssen Pharmaceutica N.V. 4-[(2-Benzothiazolyl)methylamino]-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol
US5334382A (en) * 1993-02-25 1994-08-02 Sterling Winthrop Inc. Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions
WO1996012472A1 (en) * 1994-10-24 1996-05-02 Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt Liposome composition containing selegilin
WO1996031220A1 (en) * 1995-04-03 1996-10-10 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
WO1997010828A1 (en) * 1995-09-19 1997-03-27 Weisz Paul B Therapy for tissue membrane insufficiency
WO1997049735A1 (en) * 1996-06-21 1997-12-31 Queen's University At Kingston Nerve process growth modulators

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0169725A2 (en) * 1984-07-23 1986-01-29 Ono Pharmaceutical Co., Ltd. Prostaglandin analogues for the treatment of brain cells anoxia
WO1992002256A1 (en) * 1990-08-01 1992-02-20 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
EP0501552A1 (en) * 1991-02-25 1992-09-02 Janssen Pharmaceutica N.V. 4-[(2-Benzothiazolyl)methylamino]-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol
US5334382A (en) * 1993-02-25 1994-08-02 Sterling Winthrop Inc. Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions
WO1996012472A1 (en) * 1994-10-24 1996-05-02 Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt Liposome composition containing selegilin
WO1996031220A1 (en) * 1995-04-03 1996-10-10 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
WO1997010828A1 (en) * 1995-09-19 1997-03-27 Weisz Paul B Therapy for tissue membrane insufficiency
WO1997049735A1 (en) * 1996-06-21 1997-12-31 Queen's University At Kingston Nerve process growth modulators

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDRUS, P.K. ET AL: "Neuroprotective effects of the novel brain-penetrating pyrrolopyrimidine antioxidants U-101033E and U-104067F against post-ischemic degeneration of nigrostriatal neurons", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 47, no. 6, 1997, pages 650 - 654, XP000879437 *
COHAN, S.L.. ET AL: "Effect of flunarizine on electroencephalogram recovery and brain temperature in gerbils after brain ischemia", STROKE, vol. 23, no. 2, 1992, pages 229 - 233, XP000879446 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002131746 *
HALL, E.D. ET AL: "Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine- induced degeneration of nigrostriatal neurons", BRAIN RESEARCH, vol. 742, 1996, pages 80 - 88, XP000884108 *
NONAKA, S. ET AL: "Effects of PGE1.CD on chronic focal cerebral ischemia in rats", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 20, no. 1-2, 1994, pages 186, XP000884263 *
NONAKA, S. ET AL: "Effects of PGE1-alpha-cyclodextrin on experimental cerebral ischemia", YAKURI TO CHIRYO, vol. 20, no. 12, 1992, pages 4857 - 72 *
SUN, D. ET AL: "Efffect of platelet-activating factor antagonist BN 50739 and its diluents on mitochondrial respiration and membrane lipids during and following cerebral ischemia", JOURNAL OF NEUROCHEMISTRY, vol. 62, no. 5, 1994, pages 1929 - 1938, XP000884097 *

Also Published As

Publication number Publication date
AU5050899A (en) 2000-02-14
GB9815785D0 (en) 1998-09-16
WO2000004888A2 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
AU2277501A (en) One-step system for cleansing, conditioning, and treating the skin
EP1600168A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
AU2002243370A1 (en) Body supported activity and condition monitor
AU2001279707A1 (en) Diagnosis of behavioural disorders, neurological disorders and cancer
ZA200300712B (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome.
IL164839A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
AU6910600A (en) Methods for the treatment of mental disorders
ZA200203156B (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders.
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
AU4373499A (en) Use of drug-loaded nanoparticles for the treatment of cancers
EP1106609A3 (en) Aminoalcohol derivative and medicament comprising the same
AU1546101A (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
AU4770800A (en) Body treatment product
WO2000004888A3 (en) Use of cyclodextrins for the treatment of cerebral ischaemia and central nervous system injury
AU3593599A (en) Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof
GB9919713D0 (en) New medical use of high density lipoprotein
AU5111999A (en) Active noise reduction for audiometry
AU778462C (en) Blood carbonyl compound-trapping agent
AU2092300A (en) Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
WO2000061125A3 (en) Osanetant in the treatment of mood disorders
AU3768800A (en) Treatment of brain changes with myelin protective agents
WO2001037832A3 (en) Combination of riluzole and gabapentin and use thereof as medicine
MXPA02006448A (en) Remedies for external use for allergic skin diseases.
AU6107999A (en) 1,3-benzodiazepines with integrin inhibitory activity for use in the treatment of inflammatory disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase